These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 27550021)
1. The Absorb bioresorbable vascular scaffold for the treatment of coronary artery disease. Collet C; de Winter RJ; Onuma Y; Serruys PW Expert Opin Drug Deliv; 2016 Oct; 13(10):1489-99. PubMed ID: 27550021 [TBL] [Abstract][Full Text] [Related]
2. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532 [TBL] [Abstract][Full Text] [Related]
3. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW; JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836 [TBL] [Abstract][Full Text] [Related]
4. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent. Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444 [TBL] [Abstract][Full Text] [Related]
5. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials? Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169 [TBL] [Abstract][Full Text] [Related]
6. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use. Sotomi Y; Suwannasom P; Tenekecioglu E; Tateishi H; Abdelghani M; Serruys PW; Onuma Y Expert Rev Cardiovasc Ther; 2015 Oct; 13(10):1127-45. PubMed ID: 26401921 [TBL] [Abstract][Full Text] [Related]
7. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial. Arroyo D; Gendre G; Schukraft S; Kallinikou Z; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Togni M; Cook S; Puricel S Int J Cardiol; 2017 Sep; 243():121-125. PubMed ID: 28576627 [TBL] [Abstract][Full Text] [Related]
8. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593 [TBL] [Abstract][Full Text] [Related]
9. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961 [TBL] [Abstract][Full Text] [Related]
11. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries. Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648 [TBL] [Abstract][Full Text] [Related]
12. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent. Dalos D; Gangl C; Roth C; Krenn L; Scherzer S; Vertesich M; Lang I; Maurer G; Neunteufl T; Berger R; Delle-Karth G BMC Cardiovasc Disord; 2016 May; 16():104. PubMed ID: 27225486 [TBL] [Abstract][Full Text] [Related]
13. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R). Nef H; Wiebe J; Achenbach S; Münzel T; Naber C; Richardt G; Mehilli J; Wöhrle J; Neumann T; Biermann J; Zahn R; Kastner J; Schmermund A; Pfannebecker T; Schneider S; Limbourg T; Hamm CW Cardiovasc Revasc Med; 2016; 17(1):34-7. PubMed ID: 26431767 [TBL] [Abstract][Full Text] [Related]
15. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270 [TBL] [Abstract][Full Text] [Related]
16. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495 [TBL] [Abstract][Full Text] [Related]
17. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial. Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310 [TBL] [Abstract][Full Text] [Related]
18. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Onuma Y; Serruys PW; Gomez J; de Bruyne B; Dudek D; Thuesen L; Smits P; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia H; Ormiston JA; Catheter Cardiovasc Interv; 2011 Jul; 78(1):3-12. PubMed ID: 21413120 [TBL] [Abstract][Full Text] [Related]
19. The ABSORB bioresorbable vascular scaffold: A novel, fully resorbable drug-eluting stent: Current concepts and overview of clinical evidence. Rizik DG; Hermiller JB; Kereiakes DJ Catheter Cardiovasc Interv; 2015 Oct; 86(4):664-77. PubMed ID: 26386235 [TBL] [Abstract][Full Text] [Related]